Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 12/2010

01.08.2010 | Adis Drug Evaluation

Inactivated Split-Virion Seasonal Influenza Vaccine (Fluarix®)

A Review of its Use in the Prevention of Seasonal Influenza in Adults and the Elderly

verfasst von: Monique P. Curran, Isabel Leroux-Roels

Erschienen in: Drugs | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Fluarix® is a trivalent, inactivated, split-virion influenza vaccine containing 15 μg haemagglutinin from each of the three influenza virus strains (including an H1N1 influenza A virus subtype, an H3N2 influenza A virus subtype and an influenza B virus) that are expected to be circulating in the up-coming influenza season.
Fluarix® is highly immunogenic in healthy adults and elderly, and exceeds the criteria that make it acceptable for licensure in various regions (including the US and Europe). In a large, phase III, placebo-controlled, double-blind trial conducted in the US (2004/2005) in subjects aged 18–64 years, postvaccination sero-conversion rates against the H1N1, H3N2 and B antigens were 60–78% and respective postvaccination seroprotection rates were 97–99% in Fluarix® recipients. Another phase III trial conducted in the US (2005/2006) established the noninferiority of Fluarix® versus another trivalent inactivated influenza virus vaccine in subjects aged ≥18 years, including a subgroup of elderly subjects. In annual European registration trials, Fluarix® has consistently exceeded the immunogenicity criteria set by the EU Committee for Medicinal Products for Human Use for adults and the elderly. Fluarix® demonstrated immunogenicity in small, open-label studies in at-risk subjects.
During a year when the vaccine was well matched to the circulating strain, Fluarix® demonstrated efficacy against culture-confirmed influenza A and/or B in a placebo-controlled trial in adults aged 18–64 years. In addition, Fluarix® vaccination of pregnant women demonstrated efficacy in reducing the rate of laboratory-confirmed influenza in the infants and reducing febrile respiratory illnesses in the mothers and their new-born infants in a randomized trial.
Fluarix® was generally well tolerated in adults and the elderly in well designed clinical trials and in the annual European registration trials, with most local and general adverse events being transient and mild to moderate in intensity. The most common adverse reactions in recipients of Fluarix® were pain, redness or swelling at the injection site, muscle aches, fatigue, headache and arthralgia.
In conclusion, Fluarix® is an important means of decreasing the impact of seasonal influenza viruses on adults and the elderly.
Literatur
1.
Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003 Oct 15; 37(8): 1094–101CrossRefPubMed
2.
3.
Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J 2001 Jun; 17(6): 1282–93CrossRefPubMed
4.
5.
Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000 Jan 26; 283(4): 499–505CrossRefPubMed
6.
Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004 Sep 15; 292(11): 1333–40CrossRefPubMed
7.
Kandel R, Hartshorn KL. Prophylaxis and treatment of influenza virus infection. Biodrugs 2001; 15(5): 303–23CrossRefPubMed
8.
Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: from surveillance through production to protection. Mayo Clin Proc 2010 Mar; 85(3): 257–73CrossRefPubMedPubMedCentral
9.
Webster RG, Bean WJ, Gorman OT, et al. Evolution and ecology of influenza A viruses. Microbiol Rev 1992 Mar; 56(1): 152–79PubMedPubMedCentral
10.
11.
Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009 Jul 31; 58(RR-8): 1–52PubMed
12.
GlaxoSmithKline. Fluarix™: product monograph. Rixensart, Belgium: GlaxoSmithKline Biologicals, 2008 Dec
13.
Ghedin E, Sengamalay NA, Shumway M, et al. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 2005 Oct 20; 437(7062): 1162–6CrossRefPubMed
14.
Nakajima S, Nobusawa E, Nakajima K. Variation in response among individuals to antigenic sites on the HA protein of human influenza virus may be responsible for the emergence of drift strains in the human population. Virology 2000 Aug 15; 274(1): 220–31CrossRefPubMed
15.
Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007 Sep 28; 25(39–40): 6852–62CrossRefPubMed
16.
Treanor J. Influenza vaccine: outmaneuvering antigenic shift and drift. N Engl J Med 2004 Jan 15; 350(3): 218–20CrossRefPubMed
17.
Poland GA, Jacobson RM, Targonski PV. Avian and pandemic influenza: an overview. Vaccine 2007 Apr 20; 25(16): 3057–61CrossRefPubMed
18.
Belshe RB. The origins of pandemic influenza: lessons from the 1918 virus. N Engl J Med 2005 Nov 24; 353(21): 2209–11CrossRefPubMed
19.
20.
21.
22.
23.
24.
25.
Künzel W, Engelmann H, D’Hondt E. Immune response to influenza vaccination [letter]. Lancet 1994 Jan 15; 343(8890): 173CrossRefPubMed
26.
Künzel W, Glathe H, Engelmann H, et al. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996 Aug; 14(12): 1108–10CrossRefPubMed
27.
Hehme NW, Künzel W, Petschke F, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Investig 2002; 22(11): 751–69CrossRef
28.
Saenger R, Kuenzel W, Tuerk G, et al. Influenza split vaccine: how long will it protect? [abstract plus poster]. Tenth International Congress on Infectious Diseases; 2002 Mar 11–14; Singapore
29.
Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972 Dec; 70(4): 767–77CrossRef
30.
Treanor JJ, Campbell JD, Brady RC, et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin 2005 Nov 31; 1(6): 239–44CrossRefPubMed
31.
Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis 2009 Dec 15; 200(12): 1861–9CrossRefPubMed
32.
Beran J, Wertzova V, Honegr K, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009; 9: 2CrossRefPubMedPubMedCentral
33.
Campbell JD, Chambers C, Brady R, et al. A phase III study to evaluate the immunogenicity and safety of Fluarix® compared with Fluzone® in adults in the U.S [abstract and poster]. Tenth Annual Conference on Vaccine Research; 2007 Apr 30-May 2; Baltimore (MD)
34.
Baras B, Bouveret N, Devaster JM, et al. A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respi Viruses 2008 Nov; 2(6): 251–60CrossRef
35.
Ruf BR, Colberg K, Frick M, et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004 Aug; 32(4): 191–8CrossRefPubMed
36.
Van Hoecke Ch, Prikazsky V, Uto I. Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Gerontology 1996 Jul; 42(4): 190–8CrossRefPubMed
37.
Jo YM, Song JY, Hwang IS, et al. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 2009 Apr; 81(4): 722–7CrossRefPubMed
38.
Burbach G, Bienzle U, Stark K, et al. Influenza vaccination in liver transplant recipients. Transplantation 1999 Mar 15; 67(5): 753–5CrossRefPubMed
39.
Brydak LB, Machala M, Laguna P, et al. Antibody response to influenza vaccination in splenectomized patients in Poland. J Clin Immunol 2004; 24(3): 225–36CrossRefPubMed
40.
Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk Lymphoma 1999; 32(3-4): 369–74CrossRefPubMed
41.
Del Porto F, Lagana B, Biselli R, et al. Influenza vaccine administration in patients with systemic lupus erythe-matosus and rheumatoid arthritis: safety and immunogenicity. Vaccine 2006 Apr 12; 24(16): 3217–23CrossRefPubMed
42.
Wang S, Lei H, Wang J, et al. The cellular expression in healthy subjects before and after influenza vaccination [abstract no. G1-1201]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008 Oct 25–28; Washington, DC
43.
Brokstad KA, Eriksson JC, Cox RJ, et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 2002 Apr 1; 185(7): 878–84CrossRefPubMed
44.
Guthrie T, Hobbs CG, Davenport V, et al. Parenteral influenza vaccination influences mucosal and systemic T cell-mediated immunity in healthy adults. J Infect Dis 2004 Dec 1; 190(11): 1927–35CrossRefPubMed
45.
Brokstad KA, Cox RJ, Eriksson JC, et al. High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scand J Immunol 2001 Jul-2001 31; 54(1–2): 243–7CrossRefPubMed
46.
Gioia C, Castilletti C, Tempestilli M, et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008 Jan; 14(1): 121–8CrossRefPubMedPubMedCentral
47.
Tang JW, Ngai KL, Chan PK. Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans. J Med Virol 2008 Nov; 80(11): 1992–6CrossRefPubMed
48.
Heckler R, Billot A, Engelmann H. Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine. Intervirology 2007; 50(1): 58–62CrossRefPubMed
49.
Weston WM, Chandrashekar V, Friedland LR, et al. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum Vaccin 2009 Dec 31; 5(12): 866–58CrossRef
50.
Macalalad N, Aplasca-De Los Reyes MR, Dimaano E. The candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MenACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when coadministered in adults [abstract]. Third Northern European Conference on Travel Medicine; 2010 May 26–29; Hamburg
51.
Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants [published erratum appears in N Engl J Med 2009 Feb 5; 360 (6): 648]. N Engl J Med 2008 Oct 9; 359(15): 1555–64CrossRefPubMed
52.
53.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 1979 Aug; 110(2): 105–23CrossRefPubMed
54.
Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemopro-phylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009 Apr 15; 48(8): 1003–32CrossRefPubMed
55.
56.
Dushoff J, Plotkin JB, Viboud C, et al. Mortality due to influenza in the United States: an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006 Jan 15; 163(2): 181–7CrossRefPubMed
57.
Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med 2002 Spring; 76(1): 105–15CrossRefPubMed
58.
Rajagopal S, Treanor J. Pandemic (avian) influenza. Semin Respir Crit Care Med 2007 Apr; 28(2): 159–70CrossRefPubMed
59.
Grayson ML, Melvani S, Druce J, et al. Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis 2009 Feb 1; 48(3): 285–91CrossRefPubMed
60.
Jefferson T, Foxlee R, Del Mar C, et al. Interventions for the interruption or reduction of the spread of respiratory viruses. Cochrane Database Syst Rev 2007; (4): CD006207
61.
Bell DM. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis 2006 Jan; 12(1): 81–7CrossRefPubMed
62.
Inglesby TV, Nuzzo JB, O’Toole T, et al. Disease mitigation measures in the control of pandemic influenza. Biosecur Bioterror 2006; 4(4): 366–75CrossRefPubMed
63.
Lynch 3rd JP, Walsh EE. Influenza: evolving strategies in treatment and prevention. Semin Respir Crit Care Med 2007 Apr; 28(2): 144–58CrossRefPubMed
64.
Smith JR, Ariano RE, Toovey S. The use of antiviral agents for the management of severe influenza. Crit Care Med 2010 Apr; 38 (4 Suppl.): e43–51CrossRefPubMed
65.
66.
Audsley JM, Tannock GA. Cell-based influenza vaccines: progress to date. Drugs 2008; 68(11): 1483–91CrossRefPubMed
67.
Wang Z, Tobler S, Roayaei J, et al. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 2009 Mar 4; 301(9): 945–53CrossRefPubMed
68.
69.
Tosh PK, Poland GA. Emerging vaccines for influenza. Expert Opin Emerg Drugs 2008 Mar; 13(1): 21–40CrossRefPubMed
70.
Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine 2008 Sep 12; 26 Suppl. 4: D17–22CrossRefPubMed
71.
Nicol KL, D’Heilly SJ, Greenberg ME, et al. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50–64 years. Clin Infect Dis 2009 Feb 1; 48(3): 292–8CrossRef
72.
Centers for Disease Control and Prevention. Seasonal influenza 2009–2010: ACIP vaccination recommendations [online]. Available from URL: http://​www.​cdc.​gov/​flu [Accessed 2010 Apr 14]
73.
74.
National Advisory Committee on Immunization. Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2009–2010. Can Commun Dis Rep 2009 Oct; 35 (ASC-6): 1–41
75.
76.
77.
Partridge J, Kieny MP, The World Health Organization H1N1 influenza vaccine Task Force. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009–2010 and comparison with previous estimates and global action plan targets. Vaccine 2010; 28(30): 4709–12CrossRefPubMed
78.
Collin N, de Radigues X. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 2009 Aug 20; 27(38): 5184–6CrossRefPubMed
79.
Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007 Apr 12; 25(15): 2842–51CrossRefPubMed
80.
Legrand J, Vergu E, Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 2006 Nov 10; 24(44-46): 6605–11CrossRefPubMed
81.
82.
Barr IG, McCauley J, Cox N, et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season. Vaccine 2010 Feb 3; 28(5): 1156–67CrossRefPubMed
83.
Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006 Feb 20; 24(8): 1159–69CrossRefPubMed
84.
Doherty PC, Topham DJ, Tripp RA, et al. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997 Oct; 159: 105–17CrossRefPubMed
85.
McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006 May 15; 176(10): 6333–9CrossRefPubMed
86.
Knottnerus JA. Influenza vaccination in the elderly: current evidence and uncertainties. J Clin Epidemiol 2009 Jul; 62(7): 675–6CrossRefPubMed
87.
Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994 Dec 7; 272(21): 1661–5CrossRefPubMed
88.
Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007 Oct 4; 357(14): 1373–81CrossRefPubMed
89.
Vu T, Farish S, Jenkins M, et al. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002 Mar 15; 20(13-14): 1831–6CrossRefPubMed
90.
Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001 Jul 15; 154(2): 155–60CrossRefPubMed
91.
Arden N, Monto AS, Ohmit SE. Vaccine use and the risk of outbreaks in a sample of nursing homes during an influenza epidemic. Am J Public Health 1995 Mar; 85(3): 399–401CrossRefPubMedPubMedCentral
92.
Glezen WP, Simonsen L. Commentary: benefits of influenza vaccine in US elderly. New studies raise questions. Int J Epidemiol 2006 Apr; 35(2): 352–3PubMed
93.
94.
Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; (2): CD004876
95.
Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 2006 Nov 1; 194 Suppl. 2: S133–8CrossRefPubMed
96.
Nicholson KG, Nguyen-Van-Tam JS, Ahmed AH, et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Lancet 1998 Jan 31; 351(9099): 326–31CrossRefPubMed
97.
Haber P, Sejvar J, Mikaeloff Y, et al. Vaccines and Guillain-Barre syndrome. Drug Saf 2009; 32(4): 309–23CrossRefPubMed
98.
Souayah N, Nasar A, Suri MF, et al. Guillain-Barre syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990–2005). J Clin Neuromuscul Dis 2009 Sep; 11(1): 1–6CrossRefPubMed
99.
Vellozzi C, Burwen DR, Dobardzic A, et al. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009 Mar 26; 27(15): 2077–83CrossRef
100.
McGrogan A, Madle GC, Seaman HE, et al. The epidemiology of Guillain-Barre syndrome worldwide: a systematic literature review. Neuroepidemiology 2009; 32(2): 150–63CrossRefPubMed
Metadaten
Titel
Inactivated Split-Virion Seasonal Influenza Vaccine (Fluarix®)
A Review of its Use in the Prevention of Seasonal Influenza in Adults and the Elderly
verfasst von
Monique P. Curran
Isabel Leroux-Roels
Publikationsdatum
01.08.2010
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 12/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/11205020-000000000-00000

Weitere Artikel der Ausgabe 12/2010

Drugs 12/2010 Zur Ausgabe

Adis Drug Evaluation

Glatiramer Acetate

Review Article

Triptans for the Management of Migraine

Adis Drug Profile

Roflumilast

Adis Drug Profile

Dexlansoprazole Modified Release

Adis Drug Profile

Oral Colchicine (Colcrys®)

Current Opinion

Drug or Vaccine?